Takara Bio (TYO:4974) completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.
The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.
ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.
Price (JPY): $822.00, Change: $+1.0, Percent Change: +0.12%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.